《新股消息》科笛-B(02487.HK)公開發售近下限定價21.85元 一手中籤率100%
專注於皮膚學的生物製藥商科笛-B(02487.HK)公布招股結果,每股發售價定為21.85元,為招股價範圍(20.64至24.75元)接近下限定價。香港公開發售部分錄得約0.41倍超額認購。每手200股計,一手中籤率100%人人有份。該股將於下周一(12日)掛牌。獨家保薦人為中金公司。
公司是次上市引入嘉實基金、無錫新鴻笛創投及新氧(SY.US)為基石投資者,合共認購約830.38萬股,佔緊隨全球發售完成後公司股本約2.73%。
此外,公司上市料淨集資約3.93億元,當中約45%將用於核心產品CU-20401:約22%用於撥付主要產品CU-40102及CU-10201的持續研發活動;約18%用於撥付管線中其他候選產品的持續研發活動:約10%用於管線擴展的技術開發及業務開發;約5%用作營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.